Abstract:The paradigm of non-small cell lung cancer (NSCLC) treatment has been profoundly influenced by the development of immune checkpoint inhibitors (ICI), but the range of clinical responses observed among patients poses significant challenges. To date, analyses of tumor biopsies are the only parameter used to guide prognosis to ICI therapy. Tumor biopsies, however, are often difficult to obtain and tissue-based biomarkers are limited by intratumoral heterogeneity and temporal variability. In response, there has been a growing emphasis on the development of "liquid biopsy"‒ derived biomarkers, which offer a minimally invasive means to dynamically monitor the immune status of NSCLC patients either before and/or during the course of treatment. Here we review studies in which multiple blood-based biomarkers encompassing circulating soluble analytes, immune cell subsets, circulating tumor DNA, blood-based tumor mutational burden, and circulating tumor cells have shown promising associations with the clinical response of NSCLC patients to ICI therapy. These investigations have unveiled compelling correlations between the peripheral immune status of patients both before and during ICI therapy and patient outcomes, which include response rates, progression-free survival, and overall survival. There is need for rigorous validation and standardization of these blood-based assays for broader clinical application. Integration of multiple blood-based biomarkers into comprehensive panels or algorithms also has the potential to enhance predictive accuracy. Further research aimed at longitudinal monitoring of circulating biomarkers is also crucial to comprehend immune dynamics and resistance mechanisms and should be used alongside tissue-based methods that interrogate the tumor microenvironment to guide treatment decisions and may inform on the development of novel therapeutic strategies. The data reviewed here reinforce the opportunity to refine patient stratification, optimize treatments, and improve outcomes not only in NSCLC but also in the wider spectrum of solid tumors undergoing immunotherapy.

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer

Immune checkpoint inhibitors: recent progress and potential biomarkers

Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade

Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: are we on the right path?

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

Advances and prospects of biomarkers for immune checkpoint inhibitors

Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

Tissue biomarkers of immune checkpoint inhibitor therapy

Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers

Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist's Perspective on Current Knowledge

Profiling of Immune Features to Predict Immunotherapy Efficacy

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Dynamic Peripheral Blood Immune Cell Markers for Predicting the Response of Patients with Metastatic Cancer to Immune Checkpoint Inhibitors

Biomarkers of response to PD-1/PD-L1 inhibition